Article
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Future oncology (London, England) - 1 Sept 2018
Tam Constantine S, LeBlond Veronique, Novotny William, Owen Roger G, Tedeschi Alessandra, Atwal Siminder, Cohen Aileen, Huang Jane, Buske Christian
Abstract excerpt
Waldenström macroglobulinemia (WM), an incurable B-cell malignancy, is sensitive to Bruton tyrosine kinase (BTK) inhibition with ibrutinib, a first-generation BTK inhibitor. Off-target effects of ibrutinib against TEC- and EGFR-family kinases are implicated in some adverse events. Patients with CXCR4WHIM and MYD88L265P mutations or who are MYD88WT have less sensitivity to ibrutinib than those with MYD88L265P and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.